• 5 April 2019

    Gilead submits sNDA to FDA to expand HIV label for Descovy

    Gilead has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for antiviral Descovy (emtricitabine and tenofovir alafenamide) for pre-exposure prophylaxis (PrEP) to reduce...

  • 5 April 2019

    NICE recommends BMS’ Opdivo-Yervoy combination for RCC

    Bristol-Myers Squibb (BMS) has announced that the National Institute of Health and Care Excellence (NICE) has recommends Opdivo (nivolumab) and Yervoy (ipilimumab) combination therapy to treat National Health Service (NHS)...

Go Top